Sichuan Kelun Pharmaceutical's (SHE:002422) unit, Sichuan Kelun Botai Biopharmaceutical, will conduct clinical trials on two drugs after obtaining approval from the Chinese drug administration, according to a Shenzhen Stock Exchange disclosure on Monday.
The regulator approved the clinical trials of SKB571 and SKB535.
The SKB571 has been developed as a treatment against tumors in cases, such as lung cancer and gastrointestinal tumors, while SKB535 was designed to treat advanced solid tumors, the pharmaceutical company said.
The company's shares slipped more than 2% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments